Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance T Downing, H Imamura, S Decuypere, TG Clark, GH Coombs, JA Cotton, ... Genome research 21 (12), 2143-2156, 2011 | 438 | 2011 |
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance S Rijal, B Ostyn, S Uranw, K Rai, NR Bhattarai, TPC Dorlo, JH Beijnen, ... Clinical Infectious Diseases 56 (11), 1530-1538, 2013 | 318 | 2013 |
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell, ES Istvan, AK Lukens, MG Gomez-Lorenzo, M Vanaerschot, ... Science 359 (6372), 191-199, 2018 | 167 | 2018 |
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ... Elife 5, e12613, 2016 | 137 | 2016 |
Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression F Dumetz, H Imamura, M Sanders, V Seblova, J Myskova, P Pescher, ... MBio 8 (3), e00599-17, 2017 | 134 | 2017 |
Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments BA Ejigu, D Valkenborg, G Baggerman, M Vanaerschot, E Witters, ... Omics: a journal of integrative biology 17 (9), 473-485, 2013 | 105 | 2013 |
Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background S Decuypere, M Vanaerschot, K Brunker, H Imamura, S Müller, B Khanal, ... PLoS neglected tropical diseases 6 (2), e1514, 2012 | 92 | 2012 |
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials Y Antonova-Koch, S Meister, M Abraham, MR Luth, S Ottilie, AK Lukens, ... Science 362 (6419), eaat9446, 2018 | 81 | 2018 |
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? M Vanaerschot, F Dumetz, S Roy, A Ponte-Sucre, J Arevalo, JC Dujardin Expert review of anti-infective therapy 12 (8), 937-946, 2014 | 73 | 2014 |
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain K Rai, B Cuypers, NR Bhattarai, S Uranw, M Berg, B Ostyn, JC Dujardin, ... MBio 4 (5), e00611-13, 2013 | 73 | 2013 |
Linking in vitro and in vivo survival of clinical Leishmania donovani strains M Vanaerschot, I Maes, M Ouakad, V Adaui, L Maes, S De Doncker, ... PLoS One 5 (8), e12211, 2010 | 73 | 2010 |
Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines KS Van Horn, X Zhu, T Pandharkar, S Yang, B Vesely, M Vanaerschot, ... Journal of medicinal chemistry 57 (12), 5141-5156, 2014 | 69 | 2014 |
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India P Srivastava, VK Prajapati, M Vanaerschot, G Van der Auwera, ... Infection, Genetics and Evolution 10 (7), 1145-1150, 2010 | 66 | 2010 |
Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India A Stauch, HP Duerr, JC Dujardin, M Vanaerschot, S Sundar, M Eichner PLoS neglected tropical diseases 6 (12), e1973, 2012 | 58 | 2012 |
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex T Downing, O Stark, M Vanaerschot, H Imamura, M Sanders, ... Infection, Genetics and Evolution 12 (1), 149-159, 2012 | 58 | 2012 |
LC-MS metabolomics from study design to data-analysis–using a versatile pathogen as a test case M Berg, M Vanaerschot, A Jankevics, B Cuypers, R Breitling, JC Dujardin Computational and structural biotechnology journal 4 (5), e201301002, 2013 | 57 | 2013 |
Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden M Vanaerschot, S De Doncker, S Rijal, L Maes, JC Dujardin, S Decuypere PloS one 6 (8), e23120, 2011 | 57 | 2011 |
Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure M Berg, M Vanaerschot, A Jankevics, B Cuypers, I Maes, S Mukherjee, ... Molecular microbiology 90 (2), 428-442, 2013 | 56 | 2013 |
Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race M Vanaerschot, S Huijben, F Van den Broeck, JC Dujardin FEMS microbiology reviews 38 (1), 41-55, 2014 | 55 | 2014 |
Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines M Ouakad, M Vanaerschot, S Rijal, S Sundar, N Speybroeck, L Kestens, ... Parasitology 138 (11), 1392-1399, 2011 | 53 | 2011 |